Extended-release Buprenorphine as a Novel Low-dose Induction Strategy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Opioid Use Disorder
Interventions
DRUG

Extended-release Buprenorphine

"First 10 participants will receive XR-BUP 16mg in single-blind fashion. If at least 90% of the participants who received 16mg successfully complete induction (success defined as experiencing no BPOW),10 additional participants will receive a 24mg dose in a single blind fashion.~If at least 90% who received 24mg successfully complete induction (success defined as experiencing no BPOW), 10 additional participants will receive a 32mg dose in a single blind fashion."

Trial Locations (1)

02118-5605

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

University of Utah

OTHER

lead

Brigham and Women's Hospital

OTHER